AU2019294723B2 - DOT1L degrader and uses thereof - Google Patents

DOT1L degrader and uses thereof Download PDF

Info

Publication number
AU2019294723B2
AU2019294723B2 AU2019294723A AU2019294723A AU2019294723B2 AU 2019294723 B2 AU2019294723 B2 AU 2019294723B2 AU 2019294723 A AU2019294723 A AU 2019294723A AU 2019294723 A AU2019294723 A AU 2019294723A AU 2019294723 B2 AU2019294723 B2 AU 2019294723B2
Authority
AU
Australia
Prior art keywords
certain embodiments
alkyl
unsubstituted
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019294723A
Other languages
English (en)
Other versions
AU2019294723A1 (en
Inventor
Scott Armstrong
Paul M. PARK
Jun Qi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2019294723A1 publication Critical patent/AU2019294723A1/en
Application granted granted Critical
Publication of AU2019294723B2 publication Critical patent/AU2019294723B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2019294723A 2018-06-27 2019-06-27 DOT1L degrader and uses thereof Active AU2019294723B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690791P 2018-06-27 2018-06-27
US62/690,791 2018-06-27
PCT/US2019/039368 WO2020006157A1 (en) 2018-06-27 2019-06-27 Dot1l degrader and uses thereof

Publications (2)

Publication Number Publication Date
AU2019294723A1 AU2019294723A1 (en) 2020-12-17
AU2019294723B2 true AU2019294723B2 (en) 2024-06-27

Family

ID=67263119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019294723A Active AU2019294723B2 (en) 2018-06-27 2019-06-27 DOT1L degrader and uses thereof

Country Status (6)

Country Link
US (1) US11634450B2 (enExample)
EP (1) EP3814365B1 (enExample)
JP (1) JP7821573B2 (enExample)
AU (1) AU2019294723B2 (enExample)
CA (1) CA3102856A1 (enExample)
WO (1) WO2020006157A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146561A1 (en) * 2019-01-09 2020-07-16 Dana-Farber Cancer Institute, Inc. Dot1l degraders and uses thereof
EP4323340A2 (en) 2021-04-13 2024-02-21 President and Fellows of Harvard College E3 ligase binders and uses thereof
KR102967802B1 (ko) * 2021-08-04 2026-05-22 주식회사 아이비스바이오 물질 특성이 개선된 면역조절아마이드 유도체
EP4419518A1 (en) * 2021-10-18 2024-08-28 Dana-Farber Cancer Institute, Inc. Small molecules for dot1l degradation and uses thereof
WO2023215354A1 (en) * 2022-05-03 2023-11-09 Board Of Regents, The University Of Texas System Menin proteolysis targeting chimeras (protacs)
US20240238304A1 (en) * 2022-11-17 2024-07-18 Northwestern University Small Molecule Degraders of DOT1L and Uses Thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9535067B2 (en) 2013-07-29 2017-01-03 Dana-Farber Cancer Institute, Inc. DOT1L probes
US9458165B2 (en) * 2014-08-27 2016-10-04 Dana-Farber Cancer Institute, Inc. DOT1L inhibitors

Also Published As

Publication number Publication date
WO2020006157A1 (en) 2020-01-02
US11634450B2 (en) 2023-04-25
EP3814365B1 (en) 2025-09-17
JP7821573B2 (ja) 2026-02-27
AU2019294723A1 (en) 2020-12-17
US20210130386A1 (en) 2021-05-06
CA3102856A1 (en) 2020-01-02
JP2021529174A (ja) 2021-10-28
EP3814365A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
US20230227433A9 (en) Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof
AU2017363313B2 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
AU2020263390B2 (en) Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof
AU2020362194B2 (en) A pyrazolopyrimidine derivative as a HCK inhibitor for use in therapy, in particular MYD88 mutated diseases
US11634450B2 (en) DOT1L degraders and uses thereof
AU2020301399B2 (en) HCK degraders and uses thereof
AU2019224089B2 (en) Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof
US20260028367A1 (en) Dot1l degraders and uses thereof
AU2017221422A1 (en) MAX binders as Myc modulators and uses thereof
US20220242872A1 (en) E3 ligase binders and uses thereof
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
US20230339865A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)